• Transition of CEO role

    Posted on 15 May 2013

    The Board of Photonz Corporation is delighted to announce the appointment of Dr James Campbell to the role of CEO as part of a staged transition that sees Dr Greg Collier assume the CEO role of the ASX-listed biotech company Invion Limited. 

  • Photonz's Chief Scientific Officer Wins NZBIO Award

    Posted on 20 March 2013

    Dr Hywel Griffiths, Chief Scientific Officer for Photonz Corp. was named the 2013 Young Biotechnologist of the Year by NZBIO at an award ceremony Tuesday evening.


  • Seeking commercial partners

    Posted on 9 November 2012

    AUCKLAND via ALGAE WORLD ASIA CONFERENCE SINGAPORE – 8 November 2012 – Talks are underway involving potential partners of Photonz Corporation as the company is finalising its process for manufacturing eicosapentaenoic acid (EPA) by fermentation of micro-algae.


The Product

Photonz fermentation product PNZ0901, is a drug substance comprising high purity eicosapentaenoic acid (EPA).

This product is produced using Photonz' proprietary algal fermentation technology which overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

Compared with existing methods of production the Photonz method has several significant advantages. It is; sustainable; secure; traceable; consistent; scaleable and animal-free.

Photonz owns or controls seven patent families covering fermentation and purification of microalgal EPA.